Results 161 to 170 of about 22,937 (220)

Selective Inhibitor of Protein Kinase PKN3 Generated by Conjugation of a Structurally Optimized Bumped <i>N</i>-(2-Aminoethyl)-8-anilinoisoquinoline-5-sulfonamide (H-9) with d-Arginine-Rich Chain. [PDF]

Molecules
Smorodina V, Jääger EL, Sõrmus T, Flores EJZ, Enkvist E, Uri A, Viht K.   +6 more
europepmc   +1 more source

KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. [PDF]

Cancer Res
Burge RA, Le Roux O, Popow O, Spadafora VK, Rajesh C, Adair SJ, Bialousow L, Murphy C, Saberi S, Vaena SG, Taquey MC, Allen S, Han L, Helke KL, Sharma S, Ostrowski MC, Guttridge DC, Dincman TA, Bauer TW, Kashatus DF, McFall T, Haigis KM, Hollingsworth MA, Counter CM, Der CJ, Hobbs GA.   +25 more
europepmc   +1 more source

PKブースター

Farumashia, 2017
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting DNA-PK

2023
This chapter explores the multifaceted roles of DNA-PK with particular focus on its functions in non-homologous end-joining (NHEJ) DNA repair. DNA-PK is the primary orchestrator of NHEJ but also regulates other biologic processes. The growing understanding of varied DNA-PK biologic roles highlights new avenues for cancer treatment.
Jan Philipp, Novotny, Adrian, Mariño-Enríquez, Jonathan A, Fletcher   +2 more
openaire   +2 more sources

Improvement of Pk-Anonymization

2014 IEEE 33rd International Symposium on Reliable Distributed Systems Workshops, 2014
Pk-anonymization is a data anonymization method that employs randomization. Pk-anonymization guarantees Pk-anonymity, which is an extension of probabilistic k-anonymity. To implement this method, we assign random noise to records to reduce the probability of identifying record owners to less than 1/k.
Miho Kakizawa, Chiemi Watanabe, Ryo Furukawa 0003, Tsubasa Takahashi 0001   +3 more
openaire   +1 more source

Liver pyruvate kinase (PK) isozymes in a PK‐deficient patient*

Annals of Human Genetics, 1968
SUMMARYLiver from a patient with hereditary haemolytic anaemia due to pyruvate kinase deficiency is a deficient in the ‘erythrocyte’ PK isozyme as are her erythrocytes. The chromatographic, electrophoretic, antigenic, heat stability and kinetic properties of the patient's enzyme were not different from normal.
R H, Bigley, R D, Koler
openaire   +2 more sources

Two homozygous cases of erythrocyte pyruvate kinase (PK) deficiency in Japan: PK sendai and PK shinshu

American Journal of Hematology, 1988
AbstractTwo new erythrocyte pyruvate kinase (PK) variants with severe nonspherocytic hemolytic anemia are presented. These cases are both considered to be homozygous because of the consanguineous marriages in their parents. Their erythrocyte PK's were characterized by the recommended methods of the International Committee for Standardization in ...
Kenzaburo Tani, Hisaichi Fujii, Keisuke Takahashi, Hiromi Ogura, Hitoshi Kanno, Kiyoshi Hayasaka, Kuniaki Narisawa, Tatsutoshi Nakahata, Taro Akabane, Takayuki Morisaki, Hisashi Tsutsumi, Shiro Miwa   +11 more
openaire   +2 more sources

Determination of pK's of trinucleotides

Biopolymers, 1972
AbstractpK's of trinucleotides are calculated according to the theory of Kirkwood and Westheimer for ellipsoids. In order to compare the calculated values with some experimental results, a number of trimers were prepared and their pK's were measured.
openaire   +2 more sources

The Importance of PK–PD

Journal of Medicinal Chemistry, 2023
James C. Barrow, Craig W. Lindsley
openaire   +2 more sources

[Pharmacokinetics (PK) of mAbs].

Medecine sciences : M/S, 2009
The human Fc portion of humanized monoclonal antibodies (mAb) gives them a half-life of around 21 days, similar to that of endogenous immunoglobulin G (IgG). Neonatal Fc receptor (FcRn) plays a major role in the pharmacokinetics (PK) of mAbs. By protecting them from degradation, it is responsible for their long half-life and by allowing their ...
openaire   +2 more sources